This applies, in particular, to muscle toxicity and drug-related CPK elevations [33, 67, 68], which were reported to have occurred more frequently in patients receiving daily doses > 6 mg/kg [49], but also to renal impairment [69, 70] and leukopenia [71, 72]. This evidence concerns the gene PIK3C2A and Decreased total leukocyte count.